AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36426618
Drug: Automated VR
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated VR cognitive behavior therapy (VR‐CBT) app treatment (n = 77)
Trial: 34016257
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy for VT ≥200 beats/min or VF
Trial: 34016257
Drug: Appropriate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate therapy for VT <200 beats/min or inappropriate therapy
Trial: 34016257
Drug: Combined assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined assessment of all therapy and arrhythmia types
Trial: 33120301
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg kg−1 IV
Trial: 33120301
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg kg−1 IV and Magnesium 2 g IV
Trial: 36380280
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of OK lens and 0.01% atropine eye drops
Trial: 36380280
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of OK lens and placebo
Trial: 33410736
Drug: Z-drugs
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z-drugs
Trial: 33410736
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no Z-drugs)
Trial: 34410749
Drug: Tailored Metacognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored Metacognitive Reflection and Insight Therapy (MERIT)
Trial: 34410749
Drug: Standard Metacognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Metacognitive Reflection and Insight Therapy (MERIT)
Trial: 34841124
Drug: Postponed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postponed treatment of PFPT (Control)
Trial: 32436173
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + HA gel (Group 2)
Trial: 32436173
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + HA mouth rinse + HA gingival gel (Group 4)
Trial: 35168289
Drug: Fibrin spray
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin spray alone
Trial: 35060116
Drug: Daily aroma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily aroma (sweet orange essential oil)
Trial: 37185596
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg OTO-104
Trial: 32169321
Drug: Eyelid warming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eyelid warming mask (EWM) applied for 30 min before bedtime daily for 4 weeks
Trial: 32169321
Drug: Artificial tears
RxNorm normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial tears administered as a single-use every day as needed for 4 weeks
Trial: 32169321
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group maintained normal lifestyle without treatment
Trial: 35986390
Drug: FX06 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FX06 (2 × 200 mg per day) administered intravenously for 5 consecutive days
Trial: 35986390
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously for 5 consecutive days
Trial: 36087611
Drug: Vilobelimab (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilobelimab (800 mg intravenously for a maximum of six doses on days 1, 2, 4, 8, 15, and 22)
Trial: 33215600
Drug: Adjuvant anthracycline-taxane-based
RxNorm normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant anthracycline-taxane-based chemotherapy followed by endocrine therapy
Trial: 36299885
Drug: DEX 200
RxNorm normalized name: Videx 200mg Chewable Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX 200 μg combined with sufentanil 150 μg for PCA
Trial: 36299885
Drug: DEX 400
RxNorm normalized name: Bidex 400mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX 400 μg combined with sufentanil 150 μg for PCA
Trial: 36299885
Drug: DEX 0
RxNorm normalized name: Peridex 0.12% Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX 0 μg combined with sufentanil 150 μg for PCA
Trial: 34556563
Drug: Blended learning
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended learning (individual preparation with a course handbook and videoclips, plus a single face-to-face session)
Trial: 34331752
Drug: Auricular acupressure
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular acupressure therapy at the Shen Men point and endocrine point bilaterally
Trial: 32172521
Drug: Loteprednol etabonate
RxNorm normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loteprednol etabonate gel 0.38%
Trial: 34617303
Drug: Behavioural activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural activation (BA) + Antidepressant (AD)
Trial: 34617303
Drug: Trial-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial-based cognitive therapy (TBCT) + Antidepressant (AD)
Trial: 35703373
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clobetasol 0.05% lotion and oral NAC
Trial: 35703373
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clobetasol 0.05% lotion and oral PTX
Trial: 35703373
Drug: Clobetasol 0.05%
RxNorm normalized name: CLOBETASOL 0.05% EMOLLIENT TOP CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobetasol 0.05% lotion
Trial: 35358097
Drug: Incisional negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incisional negative pressure wound therapy
Trial: 33120891
Drug: Whole-body cryotherapy
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body cryotherapy (WBC) - 3-min exposure to −120 C, twice a day for 7 days
Trial: 36270928
Drug: Lavender oil
RxNorm normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavender oil inhalation therapy for 5 min (L group)
Trial: 36270928
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of foot soak and lavender oil inhalation therapy (FL group)
Trial: 36270928
Drug: Foot soak
RxNorm normalized name: APIS MELLIFERA VENOM 2.1 g in 7 g / MENTHA PIPERITA LEAF 0.7 g in 7 g / TOCOPHEROL 1.05 g in 7 g TOPICAL LIQUID [HOUKEA Lymphatic Drainage Slimming Foot Soak Beads]
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot soak treatment for 20 min (F group)
Trial: 32527941
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and targeted therapy
Trial: 32527941
Drug: Dose-modifications (increased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-modifications (increased and reduced)
Trial: 36160398
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 μg kg−1) and butorphanol (20 μg kg−1)
Trial: 36160398
Drug: Midazolam (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.05 mg kg−1) and butorphanol (20 μg kg−1)
Trial: 35717239
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (NPWT) using PREVENA PLUS™ Incision Management System
Trial: 35906659
Drug: Structured and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured and individualized exercise intervention (9-month multimodal exercise program, 6 months supervised twice a week, followed by 3 months with one supervised and one unsupervised session)
Trial: 35247871
Drug: Durvalumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (10 mg/kg intravenously; once every 2 weeks for up to 12 months)
Trial: 32977820
Drug: Matrix Model
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix Model treatment combined with MPH
Trial: 32977820
Drug: Matrix Model
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix Model treatment
Trial: 34329624
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus doxycycline (200 mg on day 1, then 100 mg once daily for the following 6 days)
Trial: 35441345
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment initiated in 87 patients (73% of relapsed patients)
Trial: 35441345
Drug: Local therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local therapy (irradiation or surgical intervention) in 27 patients (23% of relapsed patients)
Trial: 33108201
Drug: Anti-GroEL antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-GroEL antibody
Trial: 33108201
Drug: Anti-CagA antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CagA antibody
Trial: 33108201
Drug: Anti-HP1118/Ggt, Anti-HP0516/HsIU,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-HP1118/Ggt, Anti-HP0516/HsIU, Anti-HP0243/NapA, Anti-HP1293/RpoA, Anti-HP0371/FabE, Anti-HP0875/KatA antibodies
Trial: 32100498
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) treatment at specific acupuncture points (Fengshi, Futu, Zusanli, Shangjuxu, Fenglong, Xuanzhong, Diji, Sanyinjiao) for 20-30 min, twice a day for 7 days.
Trial: 32100498
Drug: Routine rehabilitation
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine rehabilitation treatment (control group).
Trial: 32178648
Drug: Pedometer-based walking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pedometer-based walking intervention (6-month program with 3 months of pedometers and weekly step count targets)
Trial: 32822222
Drug: Microwave ablation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microwave ablation, radiotherapy, and chemotherapy
Trial: 32822222
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with pemetrexed disodium or gemcitabine hydrochloride, cisplatin chemotherapy, and conventional radiotherapy
Trial: 35543941
Drug: Head acupuncture
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Head acupuncture combined with exercise therapy
Trial: 34228612
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (an anabolic steroid) in combination with vitamin D
Trial: 34228612
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no anabolic steroid treatment)
Trial: 32100946
Drug: Guideline-directed LVAD
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed LVAD destination therapy (GD-LVAD-DT) using the HeartMate 3 (HM3) continuous flow pump
Trial: 34389340
Drug: Chemoradiotherapy (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (2 courses of 5‐fluorouracil 700 mg/m2 on days 1‐4 and cisplatin 70 mg/m2 on day 1 every 4 weeks with concurrent radiation 60 Gy)
Trial: 32475278
Drug: Microorganism-directed oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microorganism-directed oral antibiotics for three months
Trial: 32056873
Drug: Vortioxetine 10
RxNorm normalized name: vortioxetine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 10 mg once daily during the open-label period
Trial: 32056873
Drug: Vortioxetine 5
RxNorm normalized name: vortioxetine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 5 mg, 10 mg, or 20 mg
Trial: 33184726
Drug: 1-month dual
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy
Trial: 36010995
Drug: Tapentadol (TP)
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapentadol (TP) 50 to 500 mg/day
Trial: 36010995
Drug: Tapentadol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol plus Duloxetine (DLX) 60 to 120 mg/day
Trial: 34627829
Drug: 0.5 μg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 μg.kg‐1 dexmedetomidine (DEX 0.5 group)
Trial: 34627829
Drug: 1 μg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg.kg‐1 dexmedetomidine (DEX 1 group)
Trial: 33935153
Drug: Physical therapy-guided
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy-guided movement supplemented with virtual reality
Trial: 33935153
Drug: Physical therapy-guided
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy-guided movement alone without virtual reality
Trial: 32869592
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection of mouse nerve growth factor (mNGF) at various acupoints (0.3-0.5 mL, total 18 µg/2 mL)
Trial: 32869592
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of mouse nerve growth factor (mNGF) (18 µg/2 mL)
Trial: 32869592
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (Acupoint and Intramuscular)
Trial: 32869592
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection of mouse nerve growth factor (mNGF)
Trial: 32340650
Drug: Sodium Selenite
RxNorm normalized name: Sodium selenite
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sodium Selenite (SS) addition (0.3 mg Se/kg DM)
Trial: 32340650
Drug: Coated Sodium
RxNorm normalized name: psyllium seed coatings,blond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated Sodium Selenite (CSS) addition (0.1, 0.2 and 0.3 mg Se/kg DM)
Trial: 32340650
Drug: Medium Coated
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium Coated Sodium Selenite (MCSS) addition (0.2 mg Se/kg DM)
Trial: 32340650
Drug: High Coated
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Coated Sodium Selenite (HCSS) addition (0.3 mg Se/kg DM)
Trial: 36375565
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal treatment (NSPT) including oral hygiene instructions, scaling and root planing; and 0.05% Chlorhexidine mouthrinse
Trial: 36375565
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatment including oral hygiene instructions, supragingival removal of plaque and calculus and 0.05% Chlorhexidine mouthrinse
Trial: 34085475
Drug: Sham-auricular point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-auricular point therapy
Trial: 35671228
Drug: 3% PN
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3% PN in a 40% HP gel for 45 minutes (Group D)
Trial: 32449942
Drug: Prazosin 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin 16 mg/d, T.I.D.
Trial: 32212983
Drug: Fenofibrate 200
RxNorm normalized name: fenofibrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 200 mg orally once daily
Trial: 32212983
Drug: Coenzyme A
RxNorm normalized name: Coenzyme A
DrugBank: Coenzyme A (DB01992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coenzyme A 400 mg orally once daily
Trial: 33839766
Drug: Activity tracker
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity tracker intervention (Polar Loop 2) worn daily for 12 months
Trial: 34382947
Drug: AXA1125 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXA1125 24 g
Trial: 34382947
Drug: AXA1957 20.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXA1957 20.3 g
Trial: 33581097
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy for PH, primarily phosphodiesterase‐5 inhibitors
Trial: 33581097
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy for PH
Trial: 33581097
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy for PH in severe PH‐COPD
Trial: 33209019
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (10 g, two times per day for 14 days)
Trial: 35445748
Drug: Intravenous buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous buprenorphine (0.03 mg/kg)
Trial: 35445748
Drug: Intranasal buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal buprenorphine (0.03 mg/kg)
Trial: 35445748
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal buprenorphine (0.03 mg/kg)
Trial: 33806529
Drug: Melatonin 2
RxNorm normalized name: melatonin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 2 mg every night for six weeks
Trial: 35472193
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal Oxytocin (32 international units)
Trial: 35472193
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal Oxytocin
Trial: 32553118
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus berzosertib (210 mg/m2 on day 2 and day 9 of a 21-day cycle)
Trial: 32553118
Drug: Gemcitabine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine alone (1000 mg/m2 on day 1 and day 8 of a 21-day cycle)
Trial: 35076933
Drug: Digital rectal
RxNorm normalized name: BD Thermometer Digital Rectal (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital rectal examination (DRE) with delayed PSA screening at age 50
Trial: 32050792
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy combined with psychological intervention (Cognitive behavioral therapy)
Trial: 32050792
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy only (Control group)
Trial: 34294416
Drug: DCVAC/OvCa plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCVAC/OvCa plus chemotherapy (carboplatin and gemcitabine)
Trial: 35880079
Drug: S.boulardii monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S.boulardii monotherapy for 2 weeks followed by bismuth quadruple therapy if H. pylori positive after 4 weeks
Trial: 35880079
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for 6 weeks followed by bismuth quadruple therapy if H. pylori positive
Trial: 35880079
Drug: Total treatment
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total treatment effect of S.boulardii and bismuth quadruple therapy
Trial: 32593555
Drug: Brief oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief oral information and a leaflet on advanced directives (AD) provided by General Practitioners (GPs)
Trial: 35402445
Drug: CSF‐aspiration group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSF‐aspiration group (Group A) received spinal anesthesia with 10 mg of hyperbaric 0.5% bupivacaine with aspiration of 0.2 ml of CSF.
Trial: 35402445
Drug: No‐CSF‐aspiration group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No‐CSF‐aspiration group (Group B) received only 10 mg of 0.5% hyperbaric bupivacaine.
Trial: 32390454
Drug: non-efavirenz regimens
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: non-efavirenz regimens or no antiretroviral therapy
Trial: 34495173
Drug: Stratification by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratification by Degree of Clinical Severity and Abandonment Risk of Tuberculosis Treatment (SRTB)